Molecular Targeting of HuR Oncoprotein Suppresses MITF and Induces Apoptosis in Melanoma Cells

• Published in: Cancers Vol. 13; no. 2; p. 166
• Main Authors: Ahmed, Rebaz, Muralidharan, Ranganayaki, Srivastava, Akhil, Johnston, Sarah E, Zhao, Yan D, Ekmekcioglu, Suhendan, Munshi, Anupama, Ramesh, Rajagopal
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 06.01.2021; MDPI
• Subjects: Antitumor activity; Apoptosis; Cancer therapies; Cell cycle; Cell growth; Cell migration; Cell viability; Cytotoxicity; Drug resistance; Experiments; Gene silencing; HuR protein; Immunotherapy; Kinases; Lipids; MEK inhibitors; Melanocytes; Melanoma; Metastases; Metastasis; Microphthalmia-associated transcription factor; Nanoparticles; Oncoproteins; Patients; Proteins; Raf protein; siRNA; Skin cancer; Western blotting; United States > US; metastases; targeted therapy; nanoparticles; HuR; melanoma; MITF; siRNA
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers13020166

Treatment of metastatic melanoma possesses challenges due to drug resistance and metastases. Recent advances in targeted therapy and immunotherapy have shown clinical benefits in melanoma patients with increased survival. However, a subset of patients who initially respond to targeted therapy relapse and succumb to the disease. Therefore, efforts to identify new therapeutic targets are underway. Due to its role in stabilizing several oncoproteins' mRNA, the human antigen R (HuR) has been shown as a promising molecular target for cancer therapy. However, little is known about its potential role in melanoma treatment. In this study, we tested the impact of siRNA-mediated gene silencing of HuR in human melanoma (MeWo, A375) and normal melanocyte cells in vitro. Cells were treated with HuR siRNA encapsulated in a lipid nanoparticle (NP) either alone or in combination with MEK inhibitor (U0126) and subjected to cell viability, cell-cycle, apoptosis, Western blotting, and cell migration and invasion assays. Cells that were untreated or treated with control siRNA-NP (C-NP) were included as controls. HuR-NP treatment significantly reduced the expression of HuR and HuR-regulated oncoproteins, induced G1 cell cycle arrest, activated apoptosis signaling cascade, and mitigated melanoma cells' aggressiveness while sparing normal melanocytes. Furthermore, we demonstrated that HuR-NP treatment significantly reduced the expression of the microphthalmia-associated transcription factor (MITF) in both MeWo and MITF-overexpressing MeWo cells ( < 0.05). Finally, combining HuR-NP with U0126 resulted in synergistic antitumor activity against MeWo cells ( < 0.01). HuR-NP exhibited antitumor activity in melanoma cells independent of their oncogenic B-RAF mutational status. Additionally, combinatorial therapy incorporating MEK inhibitor holds promise in overriding MITF-mediated drug resistance in melanoma.